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Abstract
Background: Volunteering participants in disease studies tend to be healthier than the general population partially
due to specific enrollment criteria. Using modeling to accurately predict outcomes of cohort studies enrolling
volunteers requires adjusting for the bias introduced in this way. Here we propose a new method to account for
the effect of a specific form of healthy volunteer bias resulting from imposing disease status-related eligibility
criteria, on disease-specific mortality, by explicitly modeling the length of the time interval between the moment
when the subject becomes ineligible for the study, and the outcome.
Methods: Using survival time data from 1190 newly diagnosed lung cancer patients at MD Anderson Cancer
Center, we model the time from clinical lung cancer diagnosis to death using an exponential distribution to
approximate the length of this interval for a study where lung cancer death serves as the outcome. Incorporating
this interval into our previously developed lung cancer risk model, we adjust for the effect of disease status-related
eligibility criteria in predicting the number of lung cancer deaths in the control arm of CARET. The effect of the
adjustment using the MD Anderson-derived approximation is compared to that based on SEER data.
Results: Using the adjustment developed in conjunction with our existing lung cancer model, we are able to
accurately predict the number of lung cancer deaths observed in the control arm of CARET.
Conclusions: The resulting adjustment was accurate in predicting the lower rates of disease observed in the early
years while still maintaining reasonable prediction ability in the later years of the trial. This method could be used
to adjust for, or predict the duration and relative effect of any possible biases related to disease-specific eligibility
criteria in modeling studies of volunteer-based cohorts.
Background
Prediction models are a valuable tool for both persona-
lized risk prediction based on risk factors, and for ana-
lyzing a population of subjects who are screened for a
disease or undergo another preventative intervention,
whereby the comparison of observed versus predicted
(in the absence of intervention) number of outcomes,
such as mortality, can demonstrate whether the inter-
vention has a desired effect. However, a problem for the
generalization of results from prediction models is
posed by the so-called healthy volunteer effect. Healthy
volunteer effect or healthy volunteer bias are terms used
to describe the well-documented [1-8] observation of
lower rates of disease observed in cohorts enrolling
volunteers as compared to the general population. This
effect can be seen when volunteers are healthier than
average for the general population, which is caused in
part by the eligibility requirements of the study. We are
studying this latter effect, which is particularly notice-
able in the early years of a study. When a prediction
model uses data from a cohort of volunteers and then is
applied to the general population, the model is likely to
under-predict the number of endpoints; conversely, in a
situation when the model is fitted to data from the gen-
eral population and needs to be validated in a cohort,
the model may over-predict the number of endpoints in
the early years of follow-up. The bias is likely to be
stronger if the cohort was specifically organized to study
the disease in question and the eligibility criteria expli-
citly excluded subjects already diagnosed with the
disease or having symptoms indicative of the disease. For
example, in the context of lung cancer (LC) mortality
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expected to be stronger in the Carotene and Retinol Effi-
cacy Trial (CARET), a lung cancer chemoprevention trial
(used here for validation), as compared to Cancer Preven-
tion Study I (CPS-I) or Nurses’ Health Study (NHS) (used
for model fitting) that investigate multiple health out-
comes and do not focus specifically on lung cancer.
In this paper, we propose a method of adjusting for
biases related to disease-specific eligibility criteria
(briefly, eligibility-related bias)u s i n gas i m p l em o d e l i n g
approach. In order to adjust for the eligibility-related
bias, we assume that for each individual there is a time
interval prior to LC death in which an individual would
not be eligible or likely to volunteer for a study. For our
study, this interval is modeled as the time between clini-
cal diagnosis and death from LC. However, this time
interval may also be extended to include the presence of
symptoms prior to clinical diagnosis. Using survival time
data from newly diagnosed lung cancer patients treated
at MD Anderson Cancer Center, we estimate the distri-
bution of this time interval for lung cancer. Further, we
use an exponential distribution to approximate the
empirical distribution of this interval.
The method is then used to adjust predictions of lung
cancer mortality in the control arm of the Carotene and
Retinol Efficacy Trial (CARET) [9]. A model previously
developed [10] is able to accurately predict lung cancer
mortality in the CARET cohort for the later years of fol-
low-up (4-20) but overestimates mortality in the early
years (1-3) as seen in Figure 1 causing the cumulative
LC deaths to be overestimated as a result of the higher
predictions made for the first 3 years. There is some
indication that the eligibility-related bias in CARET is
present during the first 3 years of follow-up as seen in
the observed LC deaths (Figure 1). Although person-
years are steady in years 1-3 (additional file 1: Figure
S1), observed LC mortality is increasing rapidly over
this interval. Even though observed mortality can behave
somewhat randomly, the magnitude of increase along
with the large sample size of the cohort (N = 6877) can
be suggestive of the eligibility-related bias. Using the
proposed adjustment, we are able to accurately predict
the number of lung cancer deaths in CARET over the
entire length of follow-up.
Methods
In order to estimate the distribution of the time interval
between clinical lung cancer diagnosis and death from
lung cancer, we examined data on lung cancer survival
times from 1,190 newly diagnosed LC patients at the
University of Texas MD Anderson Cancer Center
(MDA). Ethical approval was obtained for this study
from the MD Anderson IRB. For each individual, data
on survival time from LC diagnosis, vital status, and
stage of disease at presentation were available. Median
survival times were also obtained from SEER-17 for
comparison purposes, since SEER is much more likely
to be representative of the general population. The
MDA estimates, on the other hand, represent the longer
end of the survival distribution, which in modeling
would result in fewer deaths and thus could be inter-
preted as a conservative comparison with a group
undergoing any preventative intervention.
Using the data from MDA, Kaplan-Meier (KM) survi-
val curves were generated stratified by AJCC lung can-
cer stage (I-IV). The individual survival curves by stage
were then re-weighted using the stage distribution
observed in SEER-17 [11] for lung cancers diagnosed
during the year 2000 (I: 16.22%, II: 2.91%, III: 32.64%,
I V :4 8 . 2 3 % ) ,t oo b t a i na no v e r a l ll u n gc a n c e rs u r v i v a l
curve. An exponential distribution was then used to
approximate the overall lung cancer survival curve in
order to simplify the adjustment. The parameter of this
distribution was found by using the KM estimate of the
median survival time in the overall KM curve and con-
verting it to the mean l of the exponential distribution,
using the following formula l=[1/ln(2)]xmed.
This exponential distribution is then used in conjunc-
tion with the mortality model, as an adjustment for the
eligibility-related bias, in order to simulate LC mortality
in the control arm of CARET for comparison to the
observed mortality.
Lung Cancer Mortality Model
Predictions and simulations of lung cancer mortality are
carried out using a two-stage clonal expansion (TSCE)
model [12] modified and validated by Foy et al 2010
[10]. Details about the TSCE model along with para-
meter estimates can be found in additional file 1 online.
Carotene and Retinol Efficacy Trial (CARET)
For model validation purposes, data were obtained on
the placebo-control arm of the heavy-smokers cohort of
the Carotene and Retinol Efficacy Trial (CARET) [9]
including data on 6,877 individuals (3797 males and
3080 females) (Table 1). Average observed follow-up
was 11.5 years and the longest follow-up was 19.5 years.
Data on age at enrollment to CARET, age at end of fol-
low-up, gender, and complete smoking history (age at
initiation, age at cessation, and cigarettes smoked per
day) were obtained for each individual. Also, data on
vital status and cause of death were obtained for calcu-
lating observed lung cancer-specific deaths. The
observed number of deaths was compared to the num-
ber of deaths simulated according to the TSCE model
with the adjustment for the eligibility-related bias.
Eligibility requirements for the heavy-smokers cohort
of CARET were that subjects had at least 20 pack-years
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Page 2 of 7of smoking history, were aged 50-69 at enrollment, and
were current smokers or had quit within the previous 6
years. Pre-menopausal women, those with a history of
cirrhosis or hepatitis within the 12 months prior to
enrollment, and those with a history of cancer within 5
years of enrollment were not eligible for CARET. Indivi-
duals who had taken less than 50% of the study vitamins
during the enrollment period between the first and sec-
ond visits were also excluded. Since the criteria for this
study include disease conditions, and further good
Figure 1 Observed and predicted lung cancer deaths in CARET. Black solid line denotes prediction while dashed lines are confidence limits.
Purple line denotes observed LC deaths. Top: Annual; Bottom: Cumulative.
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Page 3 of 7compliance to the vitamin protocol, we expect consider-
able healthy volunteer effect in this study including but
probably not limited to the type of bias we are studying.
However, we expect that the eligibility-related effect we
are studying is likely to dominate as the history of cir-
rhosis and any cancer, and compliance with the vitamin
protocol are not recognized specific risk factors for LC,
and because of the high lethality of LC.
Importantly, since lung cancer was not the primary
outcome for either CPS-I or NHS (used in fitting the
TSCE model), the lung cancer-specific eligibility-related
bias is likely to be absent to modest; the lung cancer
case-control study, also used for fitting, does not contri-
bute any additional bias. Therefore, the model developed
by us in Foy et al. [10] is likely to be accurate for pre-
dictions in the general population but may over-predict
lung cancer incidence and mortality in a cohort orga-
nized to study newly arising lung cancer, such as
CARET. Thus, to validate the model using CARET data,
the eligibility-related bias has to be taken into account.
Simulation of Lung Cancer Mortality
Under the TSCE model, let S(t) denote the probability
that an individual will not die of lung cancer by age t.
For each individual in CARET, S(t) depends on the indi-
vidual’s complete smoking history, d up to age t (age at
initiation of smoking, age at cessation of smoking, and
number of cigarettes smoked per day) and gender, and
will be referred to as S(t;d)w h e r et =0i sb i r t h .S i n c e
S(t;d) is dependent upon the individual’ss m o k i n gh i s -
tory up until age t, S(t;d) is equivalent for never smokers
and smokers prior to initiation. Along with smoking his-
tory and gender, the probability of an individual dying
from lung cancer during follow-up depends on the age
at enrollment, t0, and age at the end of follow-up, t1.
The following routine was used to simulate lung cancer
deaths for each individual from CARET, based on their
age and smoking history. Although the following routine
is intuitive, it is not exactly representative of the joint
distribution. In additional file 1, we show that the
underlying distribution does not differ enough to make
a difference in the case of this simulation.
For each individual a uniform(0, S(t0; d)) random vari-
able, u, was drawn.
A. If u ≤ S(t1) then no lung cancer death occurs dur-
ing follow-up and the simulation is retired.
B. If u >S(t1) then lung cancer death occurs during
follow-up at age, t*, computed by inverting the tail
function of the age at death distribution, u = S(t*).
In order to adjust for the eligibility-related bias, the
length of time between lung cancer diagnosis and
death is simulated (exponentially distributed with a
mean of 2 years) and an age at LC diagnosis is cal-
culated by subtracting from the age at death.
a. If the age at LC diagnosis is greater than the
age at enrollment the simulation is retired.
b. If the age at LC diagnosis is less than the age
at enrollment the simulation is rejected and the
individual is simulated again.
According to this routine, for a simulated individual to
die from lung cancer they must be diagnosed after the
age of enrollment and then die from the disease before
the age at the end of follow-up. If they were simulated
to die from lung cancer during follow-up but would
have been diagnosed previous to their age at enrollment,
then their simulation is repeated. The routine is pre-
formed for every individual from CARET to simulate a
single trial, and 5000 CARET trials were generated to
produce expected cumulative and annual number of
lung cancer deaths per follow-up year and correspond-
ing confidence intervals. The expected number of lung
cancer deaths is calculated as the mean of the simulated
trials and the confidence intervals are estimated using
the 2.5% and 97.5% percentiles.
Results
Figures depicting the KM survival curves by stage and
the overall KM curve, calculated as the weighted average
of the individual stage curves, are contained in the addi-
tional material for both the SEER-17 (diagnosed in the
year 2000) and the MDA data. The resulting KM esti-
mate of the median survival time is 17 months between
lung cancer diagnosis and death in the MDA patients.
Details of the calculations of the estimated interval
between diagnosis and death, a comparison of the expo-
nential approximation and the overall KM survival
curve, and stage distribution of newly diagnosed cases in
SEER-17 for the year 2000 are also included in addi-
tional file 1. SEER median survival time for LC-specific
mortality is reported as 11 months [11] for cases diag-
nosed in 2000. The corresponding exponential distribu-
tion means are therefore 2.0 years (MDA) and 1.3 years
(SEER), and both are used to predict LC deaths in
CARET.
Table 1 Characteristics of 3797 males and 3080 females
enrolled in the placebo control arm of CARET
Males Mean SD
Age 58.4 5.5
Pack-years 53 21.5
Follow-up 11.2 3.4
Females Mean SD
Age 58.2 5.4
Pack-years 44.4 18.0
Follow-up 11.8 3.1
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take into account the fact that the time from LC symp-
toms to LC death is a random variable, which is not
independent of the random time from birth to LC
death. In additional file 1, we derive a more rigorous
adjustment but then we show that it does not result in
further modification of the number of LC deaths.
As described in the Methods section, the adjustment
and the underlying TSCE model of lung cancer risk
were used to simulate LC mortality in CARET. Figure 2
shows the annual and cumulative expected and observed
lung cancer mortality using the two adjustment intervals
of 1.3 and 2.0 years, reflecting the MDA and SEER esti-
mated intervals. As Table 2 shows, there were 364 lung
cancer deaths observed in CARET over the complete
follow-up, while the model predicts 357.9 (95% CI: 322,
392) using the MDA adjustment and 377.9 (95% CI:
343, 415) using the SEER based adjustment. However,
when no adjustment is applied, the model substantially
over-predicts the mortality observed in CARET, with
413.6 predicted deaths (95% CI: 377, 451).
Discussion
The proposed adjustment is able to remove the eligibil-
ity-related bias. The interval between diagnosis and
death in this study was modeled using an exponential
distribution estimated from lung cancer survival time
data from both SEER and newly diagnosed patients at
MD Anderson Cancer Center (MDA). The median sur-
vival time of lung cancer in the patients at MD Ander-
son is equal to 17 months compared to the SEER
reported median survival of 11 months. Although SEER
provides good estimates of survival times seen in the
general population it is unknown whether these would
reflect survival times in a volunteer based cohort which
is influenced by the eligibility-related bias especially
s i n c ev o l u n t e e r st e n dt ob eh e a l t h i e rt h a nt h eg e n e r a l
population [1-8]. A more precise estimate of this
 
   
A  B 
C  D 
Figure 2 Observed and predicted lung cancer deaths in CARET using the disease status-related eligibility criteria adjustments.B l a c k
solid line denotes model prediction with dashed lines being confidence limits, and purple line denotes observed LC deaths. Simulations used
MDA data (adjustment 2.0 years) (A, yearly; B, cumulative) and SEER data (adjustment 1.3 years) (C, yearly; D, cumulative).
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observed in CARET directly, but this data is lacking for
the present study.
A previously suggested approach to deal with healthy
volunteer bias was to remove the first few years of fol-
low-up from both the predicted and observed arms [13].
The number of years to remove was chosen arbitrarily
and the approach was likely to be too conservative.
In the present paper survival data was used to esti-
mate the interval between diagnosis and death. We may
have underestimated this interval due to generally more
health conscious behavior seen in volunteers and the
health-related exclusion criteria, for example the exclu-
sion of those with a history of cirrhosis or hepatitis
within 12 months prior to enrollment in the CARET
cohort. However, we expect only a small impact of these
criteria on LC mortality prediction since the mentioned
conditions are not recognized LC risk factors and
because LC is such a fatal disease.
Adjusting for incidence-based mortality in a prediction
study may also be thought of and carried out as a
deconvolution problem. If the mortality rate and survival
time distribution are presumed known, it is possible to
use de-convolution to estima t et h ei n c i d e n c ef u n c t i o n .
Using the incidence function and survival time distribu-
tion it is then possible to remove incidence cases that
would have been diagnosed prior to enrollment as
described in Pinsky 2009[14]. The method proposed
here provides for a simple alternative and has the added
bonus of being able to manipulate the length of the
interval for example by including the presence of symp-
toms prior to diagnosis.
One limitation of this study is we did not explore a
possibility that the interval between diagnosis and death
may differ by gender and/or age at diagnosis. Survival
data would indicate that women would have a longer
survival than men; however, for the interval between
diagnosis and death, the opposite seems true when com-
paring observed deaths to person-years in each follow-
up year. As seen in additional file 1, observed LC deaths
are increasing for the first 4 years for men before level-
ing off and falling while for women the duration of the
increase is shorter, even as the observed person-years
are slowly decreasing over time. Studies concerning
survival by age at diagnosis are conflicting. Palma et al.
report no significant differences in survival for older vs.
younger patients for stage I non-small cell lung cancer
patients [15], while Chang et al. report that older
patients (over the age of 67) with stage IA tend to do
worse[16]. Yet another study by Bryant and Cerfolio
[17] report that patients under the age of 45 with Stage
I have a worse prognosis than older patients but not for
other stages. Given this information, we chose not to
include age in the model for the interval between diag-
nosis and death. However, for other conditions gender
and/or age may be important indicators of survival and
need to be included in the adjustment.
The method we propose has another limitation related
to the fact that it has been developed for the needs of a
specific application. However, the deconvolution method
described in additional file 1 is more general in the
sense that it applies to non-exponential distributions of
the interval from diagnosis to death, given the assump-
tion of independence between age at diagnosis and sur-
vival time. Even the latter can be relaxed, although it
would lead to computational difficulties. In addition, the
eligibility criterion is not necessarily absence of diagno-
sis; it might be non-occurrence of any specified disease-
related event, such as appearance of symptoms.
This method seeks to adjust for the biases caused by
specific enrollment criteria. Another bias associated with
healthy volunteer bias is self-selection bias, where health
conscious individuals are more likely to volunteer for
studies. These individuals tend to be healthier than the
general population and thus have lower mortality rates.
Pinsky et al. [18] have demonstrated a substantially
lower than expected overall mortality in both arms of
the PLCO screening trial, which was only partially
explained by the demographic and risk profile differ-
ences between the trial participants and the general
population. The authors hypothesized that subjects with
certain chronic diseases or conditions that strongly pre-
dispose to death over the next 5-10 years were unlikely
to volunteer for the PLCO. Therefore, the PLCO trial
population does not represent the general population in
terms of mortality. Since the self-selection bias is much
more difficult to quantify, the method proposed here
cannot adjust for it, which is a limitation of this study.
However, Pinsky et al [18] observed that the self-selec-
tion bias was not as influential in cancer-related mortal-
ity as it was in the overall mortality, suggesting that our
method may be sufficient to remove most of the healthy
volunteer effect on lung cancer mortality.
Conclusions
In this paper we introduced a new method of adjusting
for the eligibility-related bias when predicting the out-
come of a cohort study with specific eligibility criteria.
Table 2 Predicted and observed number of lung cancer
deaths in CARET
Overall Males Females
Observed 364 225 139
No Adjustment 413.6(377,451) 267.3(237,297) 146.6(124,170)
Adjusted
MDA (2.0 years) 357.9(322,392) 229.3(202,257) 128.3(108,150)
SEER (1.3 years) 377.9(343,415) 242.8(214,272) 135.2(113,158)
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time interval preceding the outcome being studied, in
this case death from lung cancer, when individuals
would be too sick and/or ineligible to enroll in a study.
For this method, we propose using an exponential distri-
bution to approximate the empirical distribution of the
time interval between ineligibility for the study and the
outcome of interest. In this study we approximated the
length of interval as the time between clinical lung can-
cer diagnosis and death. The mean length of this inter-
val was determined using survival time data from 1190
newly diagnosed lung cancer patients at MD Anderson.
Incorporating the resulting exponential distribution into
our existing lung cancer model, we were able to more
accurately predict the number of lung cancer deaths
observed in CARET over the entire length of follow-up,
and therefore validate our prediction model. This
method could be applied in other modeling efforts in
the prediction of outcomes for cohorts enrolling
volunteers.
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